The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know - Wikidata - awgldk - TriplyDB

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

http://www.wikidata.org/entity/Q34748124

about

Clinical impacts of a micropapillary pattern in lung adenocarcinoma: a review Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma.Pure ground-glass opacity on chest computed tomography: predictive factors for invasive adenocarcinoma Spread through alveolar spaces: An aerogenous invasion in pulmonary adenocarcinomas Risk factors for recurrence after sublobar resection in patients with small (2 cm or less) non-small cell lung cancer presenting as a solid-predominant tumor on chest computed tomography.Clinicopathological characteristics and prognosis of non-lepidic invasive adenocarcinoma presenting as ground glass opacity nodule.The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor.Lobectomy and limited resection in small-sized peripheral non-small cell lung cancer.Lymphatic invasion is a more significant prognostic factor than visceral pleural invasion in non-small cell lung cancer with tumours of 3 cm or less.Sublobar Resection Margin Width Does Not Affect Recurrence of Clinical N0 Non-small Cell Lung Cancer Presenting as GGO-Predominant Nodule of 3 cm or Less.Lobectomy versus Sublobar Resection in Non-Lepidic Small-Sized Non-Small Cell Lung Cancer.The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection.Preponderance of High-grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma.[Advance in Diagnose and Treatment Strategies of Adenocarcinoma in Situ].Margin Width of Resected Lepidic Lung Cancer Does Not Affect Recurrence After Sublobar Resection.Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma.[Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)].

P2860

Q26771950-B40A3EE0-847B-4924-9305-8AADB34C4188 Q36540304-EFF9023F-7A54-43AC-80E2-E0F3857F03A9 Q36540385-DF9B9090-D000-4811-95E6-47FB1E036D94 Q36583814-D762C9D9-331A-47B4-8445-773C008B53B4 Q37121389-4E5C4AA4-EB69-4E54-AA9E-DE8690481CD5 Q37156711-0E431AC1-7DE1-4F35-B6C9-713725333AAB Q37208639-22279405-0EA3-4847-BF17-EBDD1B3110C5 Q37329374-6DE3FE46-9E2E-4323-806A-CEB4ED9DC6BB Q37329520-E6DF1042-B942-4207-9828-81883956DF30 Q37528303-4939C1E8-BB12-41E7-B773-B0505872C53F Q38404058-3F3D5B81-8ADC-4E63-BF44-895BBC25D9C0 Q38410052-DE8EE3E8-27BE-4303-A67D-CE4D6B53C5FB Q47103097-5B886A80-9E25-4E25-BCA9-F5A7D32D29FB Q47104878-4B179FAE-559A-4E49-A270-DB5B62AC0063 Q48139582-A93ED11E-995C-4CD6-AB71-FC2CA6375D6E Q49958896-49B23BD1-C473-470A-A04F-BF82FACF4222 Q50085976-27822D04-5544-4853-AACC-1D50B52E1AE3 Q51464905-A081BECC-4EAE-4D12-ACA6-F8BAE0FFAE0F Q55452430-A6BD0952-E91C-4930-9BF5-C7B20FBAD5F0

P2860

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

http://www.wikidata.org/entity/Q34748124

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@ast

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@en

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@nl

type

label

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@ast

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@en

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@nl

prefLabel

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@ast

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@en

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@nl

P1433

Q34748124-EDF84C9D-501B-4CE2-AC2F-732BED53608D

P1476

Q34748124-B6FEF836-48CA-4CF4-887F-D2FEEEC3DD6A

P2093

Q34748124-26F2D4B1-86D7-43E9-BFC2-783C965DB16A

Q34748124-3A175CDA-6CFD-4BAD-BB16-188653F62E6F

Q34748124-65B59A4E-6347-4AB2-9A63-0672678B0FC6

Q34748124-81BEF7F0-9935-4EC8-949A-99B967F13E19

Q34748124-DB6F44AC-EBB3-405A-BEDA-912F8BACA6A2

P2860

Q34748124-009426C5-C4F0-4F06-9A81-3A26A2F748DC

Q34748124-08CF19E5-D602-440B-BD8D-CFC50DA7F363

Q34748124-0BFAAA8E-9254-4389-9045-26C38959D5C5

Q34748124-161BE897-3EFB-499F-AD33-4DB6ABE7C0BA

Q34748124-1A9C0C6F-B446-4371-9C72-2935B775C595

Q34748124-1AEE4DD3-9157-4599-A907-EBB3E928E95F

Q34748124-1C7ED7AF-F7F4-4027-A125-C269C031FF69

Q34748124-1DD3628E-73F6-4F9E-8C2F-DE8E47FCA164

Q34748124-274801C5-D41C-4CA0-9312-B92F9EFFE369

Q34748124-2B0762C3-47BD-4068-8B15-27A4EB7F637E

P304

Q34748124-91E663FF-8826-4262-94E7-8FB35BABB131

P31

Q34748124-6763F769-D4DA-428D-B288-74DD69185F29

P356

Q34748124-24229355-86C1-4E1B-9A92-2DDA344A50CF

P433

Q34748124-AB211D3A-572E-49F8-B14B-61D71456EC43

P478

Q34748124-78591EB2-197A-4688-B392-F45C91410E9E

P50

Q34748124-58D26B79-3432-478E-A4E6-6779EE3E6F50

P577

Q34748124-85A86EB3-1AD7-45F6-971A-C8EF43491990

P698

Q34748124-472B4006-5AED-49E7-A73B-BD18149A9466

P921

Q34748124-E6499FF6-E6CB-4533-B226-1EF69DD7774B

P932

Q34748124-3CCA76BB-CB8B-4B3E-B572-29366EAE3DCE

P356

J.SEMTCVS.2014.09.002

P1433

Seminars in thoracic and cardiovascular surgery

P1476

The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know

@en

P2093

Bernard J Park

http://www.w3.org/2001/XMLSchema#string

David R Jones

http://www.w3.org/2001/XMLSchema#string

Kyuichi Kadota

http://www.w3.org/2001/XMLSchema#string

Prasad S Adusumilli

http://www.w3.org/2001/XMLSchema#string

Takashi Eguchi

http://www.w3.org/2001/XMLSchema#string

P2860

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.

Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis.

Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease

Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung

Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm.

The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

P304

210-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMTCVS.2014.09.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

William D. Travis

P577

2014-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25527015

http://www.w3.org/2001/XMLSchema#string

P921

P932

4272758

http://www.w3.org/2001/XMLSchema#string